NCT06060587 2025-10-22
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
Phase 2 Withdrawn
Clinical Trials
63 trialsNCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT05046782 2025-09-30
Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT04569461 2025-07-04
TALON
Duke University
Phase 2 Withdrawn
NCT03581500 2025-04-23
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05815316 2025-04-13
18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
IRCCS San Raffaele
Phase 2 Withdrawn
NCT03035357 2024-05-03
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04243941 2024-03-21
PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT05574712 2024-03-18
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT05034562 2024-03-07
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04781374 2023-07-11
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
Beth Israel Deaconess Medical Center
Phase 2 Withdrawn
NCT04995978 2023-06-23
Insulin Resistance and Androgen Deprivation Therapy
St. Louis University
Phase 2 Withdrawn
NCT00771017 2023-05-25
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT04483414 2023-05-19
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT05705700 2023-02-27
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT01802307 2021-05-11
Focal Therapy for Prostate Cancer
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT02497638 2021-04-19
LIGAND
University Health Network, Toronto
Phase 2 Withdrawn
NCT04585932 2021-01-20
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03173859 2020-11-18
AERA
University of Athens
Phase 2 Withdrawn
NCT01859689 2020-07-27
Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04272645 2020-07-15
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT02811809 2020-02-27
Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT02538432 2019-11-04
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT02252978 2018-07-05
Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT01188408 2018-03-12
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
INSYS Therapeutics Inc
Phase 2 Withdrawn
NCT00003534 2018-01-31
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
Burzynski Research Institute
Phase 2 Withdrawn
NCT02793219 2017-10-30
Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT02793765 2017-10-30
Docetaxel Followed by Provenge in Metastatic Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT02810886 2017-08-22
ProsPERo
Jules Bordet Institute
Phase 2 Withdrawn
NCT00003622 2017-07-13
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
George Washington University
Phase 2 Withdrawn
NCT01087580 2017-03-03
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT00598858 2016-12-08
2007-5904
University of California, Irvine
Phase 2 Withdrawn
NCT02645591 2016-11-22
Randomized AmnioFix Study During Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02656563 2016-10-14
RAND
Canadian Urology Research Consortium
Phase 2 Withdrawn
NCT02621190 2016-08-17
CARVE
Erasmus Medical Center
Phase 2 Withdrawn
NCT02678520 2016-07-22
Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients
University of Kansas Medical Center
Phase 2 Withdrawn
NCT00003858 2016-07-13
Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence
Alliance for Clinical Trials in Oncology
Phase 2 Withdrawn
NCT01658527 2016-06-10
TAK-700 in Castration Resistant Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT01530984 2015-10-05
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT01561482 2015-07-22
Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Baylor College of Medicine
Phase 2 Withdrawn
NCT02424513 2015-06-02
A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer
ImaginAb, Inc.
Phase 2 Withdrawn
NCT02420587 2015-04-20
AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00694291 2015-03-06
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT02159690 2015-01-26
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Johns Hopkins University
Phase 2 Withdrawn
NCT02065323 2015-01-19
A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT
Comprehensive Cancer Centers of Nevada
Phase 2 Withdrawn
NCT01734681 2014-02-19
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
GenSpera, Inc.
Phase 2 Withdrawn
NCT01409473 2014-02-12
Prostate SBRT
Rocky Mountain Cancer Centers
Phase 2 Withdrawn
NCT00681148 2013-11-21
Botulinum Toxin Injection With Prostate Brachytherapy
Emory University
Phase 2 Withdrawn